drugset / Trial / NCT03881761
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma
Timeline
- Start
- 2019-02-01
- Primary completion
- 2021-01-31
- Completion
- 2022-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/CD20 bispecific CAR-T cells | Unknown | 1e+06 cells/kg | — |
| Subject | CD19/CD20 bispecific CAR-T cells | Unknown | 3e+06 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 800 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |